Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03260894 · ClinicalTrials.gov registry record · Phase 3

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

A Phase 3 study of Renal Cell Carcinoma (RCC), sponsored by Incyte Corporation.

Completed
Registry status
Phase 3
Development phase
129
Enrollment target
20
Study locations

NCT03260894 is a Phase 3 study of Renal Cell Carcinoma (RCC) that has completed, run by Incyte Corporation. The registered enrollment target is 129 participants, below the 430-participant average among 11 other Renal Cell Carcinoma (RCC) trials with a reported enrollment target (70% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03260894, a Phase 3 study of Renal Cell Carcinoma (RCC), has completed, sponsored by Incyte Corporation.

COMPLETED
Registry status
Phase 3
Development phase
129 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not received prior systemic therapy for their mRCC.

Conditions Studied

Renal Cell Carcinoma (RCC)

Interventions

  • DRUG Pembrolizumab
  • DRUG Epacadostat
  • DRUG Sunitinib
  • DRUG Pazopanib

Study Locations (20)

Arizona

  • Pinnacle Oncology Hematology - Scottsdale
  • Scottsdale Healthcare - Scottsdale
  • Arizona Oncology Associates PC- HOPE - Tucson

California

  • Cedars-Sinai Medical Center - Los Angeles
  • UC Irvine Comprehensive Cancer Center/Chao Family Comprehensive Cancer Center - Orange
  • UC Davis Comprehensive Cancer Center - Sacramento

Georgia

  • Northside Hospital - Atlanta
  • Atlanta Cancer Care - Conyers - Conyers
  • Northwest Georgia Oncology Centers Pc - Marietta

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana Farber Cancer Institute - Boston

New York

  • New York Oncology Hematology P.C - Albany
  • Memorial Sloan Kettering Cancer Center - New York

Tennessee

  • University of Tennessee Erlanger Oncology & Hematology - Chattanooga
  • The West Clinic, P.C. - Germantown

Florida

  • Woodlands Medical Specialists, PA - Pensacola

Illinois

  • Rush University Medical Center - Chicago

Trial Details

FieldValue
Enrollment Target 129 participants
Start Date 2017-12-07
Est. Completion 2025-06-04
Phase Phase 3

Sponsor

Incyte Corporation

239 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03260894

The ClinicalTrials.gov registry entry for NCT03260894 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 430-participant average among 11 other Renal Cell Carcinoma (RCC) trials with a reported enrollment target (70% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Renal Cell Carcinoma (RCC) appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.

NCT03260894 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Arizona, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT03260894 about?

NCT03260894 is a clinical study titled "Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)". The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat compared to sunitinib or pazopanib in participants with locally advanced/metastatic renal cell carcinoma (mRCC) with a clear cell component who have not received prior systemic therapy for their mRCC.

What is the current status of trial NCT03260894?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 129 participants. The study started on 2017-12-07. Estimated completion is 2025-06-04.

What conditions does trial NCT03260894 study?

This clinical trial studies the following conditions: Renal Cell Carcinoma (RCC).

What interventions are being tested in trial NCT03260894?

The interventions under investigation include: Pembrolizumab (DRUG), Epacadostat (DRUG), Sunitinib (DRUG), Pazopanib (DRUG).

Who is sponsoring clinical trial NCT03260894?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03260894 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Renal Cell Carcinoma (RCC)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Renal Cell Carcinoma (RCC)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.